Drug Trial Radar · NCT03515538
Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers
Last checked: Nov 19, 2026Latest source record: Nov 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
53
Actual
Start
Jul 12, 2018
Primary completion
Oct 22, 2019
Study completion Oct 8, 2020
Sponsor
- Lead sponsor
- EpicentRx, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Prothex, Inc.
- First posted
- May 3, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the duration or length of severe oral mucositis in patients with head and neck cancers. All patients in this study will receive 7 weeks of standard of care radiation therapy given with the chemotherapy agent, cisplatin. Patients in arms 1, 2 and 3 will also receive RRx-001 on different schedules.
Conditions
- Oral Mucositis
Interventions
RRx-001Drug
RRx-001 for injection
Cisplatin for injectionDrug
Patients will receive 3 doses of cisplatin at 100 mg/m2 in accordance with applicable guidelines such as NCCN; however, these guidelines are not intended to supersede or replace institutional guidelines with respect to appropriate and necessary care for individual patients
Radiation TherapyRadiation
Intensity Modulated Radiation Therapy (IMRT) in accordance with the American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for IMRT) is mandatory for this study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Duration of Severe Oral Mucositis (SOM)Time frame: From start of treatment through 28 days post treatment for up to 11 weeks from Start of Treatment
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
John Wayne Cancer Institute @ Providence St. John's Health Center
Santa Monica, California
Centura Health Research Center
Denver, Colorado
George Washington University
Washington D.C., District of Columbia
Florida Hospital
Orlando, Florida
Montefiore Medical Center
The Bronx, New York
East Carolina University
Greenville, North Carolina
University of Cincinnati Medical Center
Cincinnati, Ohio
Ohio State University
Columbus, Ohio
Thomas Jefferson University
Philadelphia, Pennsylvania
Ballad Health
Johnson City, Tennessee
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
UT Southwestern
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.